Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Prasannavenkatesh Durai; Maria Batool; Masaud Shah; Sangdun Choi

doi:10.1038/EMM.2015.76

Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Prasannavenkatesh Durai, Maria Batool, Masaud Shah, Sangdun Choi

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~ 487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading’ of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.

Original language	English
Article number	e181
Journal	Experimental and Molecular Medicine
Volume	47
Issue number	8
DOIs	https://doi.org/10.1038/EMM.2015.76
State	Published - Aug 2015
Externally published	Yes

Funding

This work was supported by the Mid-Career Researcher Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology (NRF-2015R1A2A2A09001059) and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI14C1992). This work was also partially supported by a grant from the Priority Research Centers Program (NRF 2012-0006687).

Funders	Funder number
Priority Research Centers Program	2012-0006687
Korea Health Industry Development Institute	HI14C1992
National Research Foundation of Korea
Ministry of Education, Science and Technology	NRF-2015R1A2A2A09001059

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/EMM.2015.76

Cite this

@article{50c8370038314a8ab8673ab7305e3e54,

title = "Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control",

abstract = "Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~ 487 deaths, have been reported worldwide. Notably, the recent human-to-human {\textquoteleft}superspreading{\textquoteright} of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.",

author = "Prasannavenkatesh Durai and Maria Batool and Masaud Shah and Sangdun Choi",

year = "2015",

month = aug,

doi = "10.1038/EMM.2015.76",

language = "English",

volume = "47",

journal = "Experimental and Molecular Medicine",

issn = "1226-3613",

publisher = "Springer Nature [academic journals on nature.com]",

number = "8",

}

TY - JOUR

T1 - Middle East respiratory syndrome coronavirus

T2 - transmission, virology and therapeutic targeting to aid in outbreak control

AU - Durai, Prasannavenkatesh

AU - Batool, Maria

AU - Shah, Masaud

AU - Choi, Sangdun

PY - 2015/8

Y1 - 2015/8

N2 - Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~ 487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading’ of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.

AB - Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~ 487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading’ of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85016626167&partnerID=8YFLogxK

U2 - 10.1038/EMM.2015.76

DO - 10.1038/EMM.2015.76

M3 - Article

C2 - 26315600

AN - SCOPUS:85016626167

SN - 1226-3613

VL - 47

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

IS - 8

M1 - e181

ER -

Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this